Forte Biosciences (FBRX) Convertible Debt (2016 - 2017)
Forte Biosciences' (FBRX) quarterly Convertible Debt came in at $11.0 million in Q1 2017, up 224.19% on a QoQ basis from $3.4 million in Q4 2016.
Forte Biosciences (FBRX) Convertible Debt (2016 - 2017) Analysis & Trends
Forte Biosciences (FBRX) has 2 years of Convertible Debt data on file, last reported at $11.0 million in Q1 2017.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $11.0 million in Q1 2017; TTM through Mar 2017 was $11.0 million, a N/A change from a year earlier, with the FY2016 full-year figure at $3.4 million, changed N/A from the prior year.
- Convertible Debt for Q1 2017 stood at $11.0 million, up from $3.4 million in the prior quarter.
- Over the last five years, Convertible Debt for FBRX reached as high as $11.0 million in Q1 2017 and fell as low as $3.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 11.02 Mn |
| Dec 31, 2016 | 3.40 Mn |